Innate Pharma SA banner

Innate Pharma SA
NASDAQ:IPHA

Watchlist Manager
Innate Pharma SA Logo
Innate Pharma SA
NASDAQ:IPHA
Watchlist
Price: 1.772 USD -0.45% Market Closed
Market Cap: $143.4m

Wall St Price Targets

IPHA Price Targets Summary
Innate Pharma SA

Wall Street analysts forecast IPHA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IPHA is 6.124 USD with a low forecast of 5.1 USD and a high forecast of 7.305 USD.

Lowest Forecast
Price Target
5.1 USD
188% Upside
Average Forecast
Price Target
6.124 USD
246% Upside
Highest Forecast
Price Target
7.305 USD
312% Upside
Innate Pharma SA Competitors:
Price Targets
SMCP
SMCP SA
77% Upside
NYXH
Nyxoah SA
356% Upside
HCAT
Health Catalyst Inc
-10% Downside

Revenue
Forecast

-7% / Year
Past Growth
92% / Year
Estimated Growth
Estimates Accuracy
-24%
Average Miss
-7% / Year
Past Growth
92% / Year
Estimated Growth
Estimates Accuracy
-24%
Average Miss

Over the last 14 years, the compound annual growth rate for Revenue has been -7%. The projected CAGR for the next 7 years is 92%.

Gross Profit
Forecast

N/A
Past Growth
1 086% / Year
Estimated Growth
Estimates Accuracy
-32%
Average Miss
N/A
Past Growth
1 086% / Year
Estimated Growth
Estimates Accuracy
-32%
Average Miss

The compound annual growth rate for Gross Profit over the next 3 years is 1 086%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
14%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
14%
Average Beat

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
15%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
15%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
43%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
43%
Average Beat
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is IPHA's stock price target?
Price Target
6.124 USD

According to Wall Street analysts, the average 1-year price target for IPHA is 6.124 USD with a low forecast of 5.1 USD and a high forecast of 7.305 USD.

What is the Revenue forecast for Innate Pharma SA?
Projected CAGR
92%

Over the last 14 years, the compound annual growth rate for Revenue has been -7%. The projected CAGR for the next 7 years is 92%.

What is the Gross Profit forecast for Innate Pharma SA?
Projected CAGR
1 086%

The compound annual growth rate for Gross Profit over the next 3 years is 1 086%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett